Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Sale Of Orthopedic Assets Will Grant European Autonomy To Biomet

This article was originally published in The Gray Sheet

Executive Summary

Biomet will redouble European sales and marketing efforts after assuming 100% ownership of its joint venture with Merck KGaA, the firm says

You may also be interested in...



Biomet Shooting For Hip, Knee, Shoulder Indications With Compress System

Biomet will seek additional indications later this year for its recently approved Compress distal femoral replacement system

Biomet Shooting For Hip, Knee, Shoulder Indications With Compress System

Biomet will seek additional indications later this year for its recently approved Compress distal femoral replacement system

Biomet Vanguard Minimally Invasive Knee System To Launch By November

Biomet believes its Vanguard series instrumented, minimally invasive unicondylar knee system will help grow the company's 40% U.S. market share in unicompartmental knees

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel